Now showing 1 - 10 of 12
  • 2018Journal Article
    [["dc.bibliographiccitation.firstpage","627"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","633"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","von Hardenberg, Jost"],["dc.contributor.author","Worst, Thomas S."],["dc.contributor.author","Westhoff, Niklas"],["dc.contributor.author","Erben, Philipp"],["dc.contributor.author","Fuxius, Stefan"],["dc.contributor.author","MĂĽller, Markus"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Weiss, Christel"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2020-12-10T18:37:50Z"],["dc.date.available","2020-12-10T18:37:50Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1159/000490618"],["dc.identifier.eissn","2296-5262"],["dc.identifier.issn","2296-5270"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77109"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2012Journal Article
    [["dc.bibliographiccitation.firstpage","1136"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Endourology"],["dc.bibliographiccitation.lastpage","1141"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Heinzelmann, Kathrin"],["dc.contributor.author","Ritter, Manuel"],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Trojan, Lutz"],["dc.date.accessioned","2018-11-07T09:06:27Z"],["dc.date.available","2018-11-07T09:06:27Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose: To determine whether previous transurethral resection of the prostate (TURP) compromises the surgical outcome and pathologic findings in patient who underwent either radical robot-assisted laparoscopic prostatectomy (RALP) or open retropubic radical prostatectomy (RRP) after TURP, because TURP is reported to complicate radical prostatectomy and there are conflicting data. Patients and Methods: From July 2008 to July 2010, 357 patients underwent RALP. Of these, 19 (5.3%) patients had undergone previous TURP. Operative and perioperative data of patients were compared with those of matched controls selected from a database of 616 post-RRP patients. Matching criteria were age, clinical stage, the level of preoperative prostate-specific-antigen, the biopsy Gleason score, the American Society of Anesthesiologists classification score, and prostate volume assessed during transrectal ultrasonography. All RRP and RALP procedures were performed by experienced surgeons. Results: Mean time to prostatectomy was 67.4 months in the RALP group and 53.1 months in the RRP group. Mean operative time was 217 +/- 51.9 minutes for RALP and 174 +/- 57.7 minutes for RRP (P < 0.05). The overall positive surgical margin rate was 15.8% in both groups (pT(2) tumors: 10.5% for RALP and 5.3% for RRP; P = 1.0). Mean estimated blood loss was 333 +/- 144 mL in RALP patients and 1103 +/- 636 mL in RRP patients (P < 0.001). The difference between preoperative and postoperative hemoglobin levels was 3.22 +/- 0.98 g/dL for RALP and 5.85 +/- 1.95 g/dL for RRP (P = 0.0002). The RALP and RRP groups also differed in terms of hospital stay (8.58 +/- 1.17 vs 11.74 +/- 5.22 days; P = 0.0037), duration of catheterization (7.95 +/- 5.69 vs 11.78 +/- 6.97 days; P = 0.0016), postoperative complications according to the Clavien classification system (6 vs 15 patients; P = 0.0027), and transfusion rate (0% vs 10.5%; P < 0.001). Conclusion: RALP offers advantages over open radical prostatectomy after previous surgery. Although both techniques are associated with adequate surgical outcomes, RALP appeared to be preferable in our population of patients with previous prostate surgery."],["dc.identifier.isi","000308374000006"],["dc.identifier.pmid","22489895"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25565"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc"],["dc.relation.issn","0892-7790"],["dc.title","Radical Prostatectomy After Previous Transurethral Resection of the Prostate: Robot-Assisted Laparoscopic Versus Open Radical Prostatectomy in a Matched-Pair Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details PMID PMC WOS
  • 2016Journal Article
    [["dc.bibliographiccitation.firstpage","66"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Urology Annals"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Echtle, Dieter"],["dc.contributor.author","Hasselhof, ViktoriaM"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2020-12-10T18:47:43Z"],["dc.date.available","2020-12-10T18:47:43Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.4103/0974-7796.163795"],["dc.identifier.issn","0974-7796"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78862"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Metal telescopic and Amplatz sheath dilation in nephrolithotomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2016Journal Article
    [["dc.bibliographiccitation.firstpage","407"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","World Journal of Urology"],["dc.bibliographiccitation.lastpage","411"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Pfalzgraf, D."],["dc.contributor.author","Rafail, B."],["dc.contributor.author","Ritter, M."],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Trojan, Lutz"],["dc.date.accessioned","2018-11-07T10:17:56Z"],["dc.date.available","2018-11-07T10:17:56Z"],["dc.date.issued","2016"],["dc.description.abstract","Objective To evaluate urethral catheter (UC) versus suprapubic tube (SPT) without stenting the anastomosis at robot-assisted radical prostatectomy (RALP) regarding surgical outcome and catheter-associated discomfort. One year after surgery, continence and patient satisfaction were evaluated. Materials and methods Sixty-two patients undergoing RALP were prospectively randomized to urinary drainage with UC or with SPT. Functional results were assessed with standardized questionnaires (IPSS, IPSS Bother Score, IIEF and Visual Analogue Scale) preoperatively, after catheter removal and 1 year after surgery. Moreover, bother by the catheter as well as pain due to the catheter was assessed. Results At personal hygiene, SPT was significantly less bothersome on the day of surgery as well as POD 1-6. Pain caused by the catheter did not differ significantly between the two groups except for POD 5 and 6, when the SPT performed significantly better. Differences regarding voiding parameters after catheter removal did not reach statistical significance. One year after surgery, no significant difference between the two groups was found regarding urinary function and IPSS. Though not statistically significant either, the need for the incision of bladder neck contracture (BNC) in two patients in the UC group is of note, as in the SPT group, no BNC occurred. Conclusion Draining the bladder with SPT only is a feasible option in patients undergoing RALP. Patients with SPT are significantly less bothered by the catheter at personal and genital hygiene compared to UC. The risk of BNC seems to be reduced in the SPT group."],["dc.identifier.doi","10.1007/s00345-015-1678-1"],["dc.identifier.isi","000371052400015"],["dc.identifier.pmid","26337521"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41326"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-8726"],["dc.relation.issn","0724-4983"],["dc.title","Transurethral versus suprapubic catheter at robot-assisted radical prostatectomy: a prospective randomized trial with 1-year follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2017Journal Article
    [["dc.bibliographiccitation.firstpage","625"],["dc.bibliographiccitation.journal","International Journal of Women's Health"],["dc.bibliographiccitation.lastpage","630"],["dc.bibliographiccitation.volume","Volume 9"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Echtle, Dieter"],["dc.contributor.author","Aboumarzouk, Omar M"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2021-06-01T10:48:32Z"],["dc.date.available","2021-06-01T10:48:32Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.2147/IJWH.S134239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85972"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1179-1411"],["dc.title","Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2017Journal Article
    [["dc.bibliographiccitation.firstpage","201"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Stumm, Lisa"],["dc.contributor.author","Ritter, Manuel"],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Trojan, Lutz"],["dc.date.accessioned","2020-12-10T18:37:48Z"],["dc.date.available","2020-12-10T18:37:48Z"],["dc.date.issued","2017"],["dc.description.abstract","Objectives: To evaluate in a prospective, controlled, nonrandomized study the surgical stress and acute-phase systemic response in robotic-assisted laparoscopic prostatectomy (RALP) compared to open radical retro-pubic prostatectomy (ORRP) by measuring humoral mediators. Methods: Forty consecutive patients undergoing either RALP or ORRP were prospectively included to assess the extent of systemic response. Blood samples were collected before surgery (T1), at the time of prostatectomy (T2), at the time of wound closure (T3), and 12 h (T4), 24 h (T5), and 48 h (T6) after surgery, and assayed for interleukins (IL-6 and IL-10), C-reactive protein (CRP), and hemoglobin. A 2-sided p \\u0026lt; 0.05 was considered to indicate significance. Results: Baseline levels of IL-6, IL-10, and CRP were comparable in both arms of the study. IL-6 and IL-10 increased in both groups during surgery and reached maximum levels at 12 and 24 h after surgery. The RALP and RRP groups differed significantly at T2 (p = 0.009), T3 (p = 0.046), T5 (p = 0.05) and T6 (p = 0.0007) for IL-6, and at T3 (p = 0.05) and T4 (p = 0.05) for IL-10. CRP levels differed significantly at 48 h postoperative (p = 0.0053). The maximum levels of all 3 mediators in the RALP group were significantly lower than those in the open surgery group. Patients in the RALP group experienced less pain from day 2 to 4 according to the Visual Analog Scale (p \\u0026lt; 0.05). Conclusions: The study suggests that IL-6 and IL-10 are useful objective markers for surgical stress and that tissue trauma and activation of post-aggression metabolism seem to be less in RALP compared to ORRP."],["dc.identifier.doi","10.1159/000478027"],["dc.identifier.eissn","1423-0399"],["dc.identifier.issn","0042-1138"],["dc.identifier.pmid","28768259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77099"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0399"],["dc.relation.issn","0042-1138"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2016Journal Article
    [["dc.bibliographiccitation.firstpage","613"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","619"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","von Hardenberg, Jost"],["dc.contributor.author","Schwartz, Maike"],["dc.contributor.author","Werner, Thorsten"],["dc.contributor.author","Fuxius, Stefan"],["dc.contributor.author","Mueller, Markus"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Weiss, Christel"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2018-11-07T10:14:16Z"],["dc.date.available","2018-11-07T10:14:16Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUNDAbiraterone Acetate (AA) represents a highly effective androgen-receptor (AR) axis targeted agent. Treatment with AA in castration-resistant prostate cancer (CRPC) may partly mediate neuroendocrine differentiation (NED) as an escape mechanism, which may have implications for the choice of sequential therapy in CRPC. We evaluated how treatment with AA influences circulating neuromediators chromogranin A (CGA), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (Pro-GRP) in chemotherapy-naive CRPC patients. METHODSWe conducted an analysis in chemotherapy-naive CRPC patients with clinical or radiographic progression of disease. A total of 35 patients were included at five institutions between February 2013 and December 2014. Sixteen of them had received AA. Serum samples were obtained before a docetaxel-based chemotherapy and analyzed in a reference laboratory. Univariable and multivariable analyses were performed to test the influence of AA treatment, its duration of treatment, and other clinicopathological variables on circulating neuromediators. RESULTSCGA and NSE levels were above the upper limit of normal (ULN) in n=20 (57.1%) and n=13 (37.1%), respectively. Treatment with AA and duration of treatment were not associated with levels above the ULN (CGA and NSE) or higher levels (Pro-GRP) of neuromediators. CGA levels were associated with age (P=0.092), lymph node metastasis (P=0.014), duration of androgen deprivation therapy (ADT; P=0.083), and intake of proton pump inhibitors (P=0.069). Pro-GRP levels were significantly associated with PSA levels (P=0.002). On multivariate analysis, CGA levels above the ULN were significantly correlated with ADT (P=0.01) and intake of proton pump inhibitors (P=0.03). CONCLUSIONSCirculating neuromediators in chemotherapy-naive CRPC patients were elevated in a high percentage of patients. ADT was found to be a relevant NED driver in this cohort. Our results may imply that patients with CRPC after first-line treatment with AA in CRPC are not at a higher risk for developing NED. The major limitation of the study represents the one-time analysis of neuromediators. Larger studies with serial blood measurements or biopsy analysis before and after treatment are needed to confirm our results. Prostate 76:613-619, 2016. (c) 2016 Wiley Periodicals, Inc."],["dc.description.sponsorship","Sanofi-Aventis Deutschland GmbH"],["dc.identifier.doi","10.1002/pros.23152"],["dc.identifier.isi","000373932700001"],["dc.identifier.pmid","26779767"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40589"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2012Review
    [["dc.bibliographiccitation.artnumber","140"],["dc.bibliographiccitation.journal","Diagnostic Pathology"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Kessel, Felix J."],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2018-11-07T09:04:40Z"],["dc.date.available","2018-11-07T09:04:40Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Leiomyomas are benign tumours that originate from smooth muscles. They are often seen in the uterus, but also in the renal pelvis, bladder, spermatic cord, epididymis, prostate, scrotum or the glans penis. Leiomyomas of the tunica albuginea are extremely rare. Case presentation: A 59-year-old white male has noted an asymptomatic tumour on the right side of his scrotal sac for several years. This tumour has increased slowly and caused local scrotal pain. An inguinal incision was performed, in which the hypoplastic testis, the epididymis and the tumour could be easily mobilized. Macroscopically the tumour showed a solid round nonencapsulated whorling cut surface. Histologically the diagnosis of a leiomyoma was made. Conclusion: We report here a very interesting and rare case of a leiomyoma of the tunica albuginea. Leiomyomas can be a possible differential diagnosis in this area."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/1746-1596-7-140"],["dc.identifier.isi","000311244000001"],["dc.identifier.pmid","23044187"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8192"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25162"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1746-1596"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Leiomyoma of the tunica albuginea, a case report of a rare tumour of the testis and review of the literature"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2013Journal Article
    [["dc.bibliographiccitation.firstpage","1699"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","1709"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2018-11-07T09:18:22Z"],["dc.date.available","2018-11-07T09:18:22Z"],["dc.date.issued","2013"],["dc.description.abstract","BACKGROUNDThe primary therapeutic target for non-organ-confined prostate cancer is the androgen receptor (AR). Main strategies to ablate AR function are androgen depletion and direct receptor blockade by AR antagonists. However, incurable castration resistant prostate cancer (CRPC) develops resistance mechanisms to cope with trace amounts of androgen including AR overexpression and mutation in the AR ligand binding domain. METHODSThe CRPC cell model VCaP derivative of a prostate cancer bone metastasis was used in vitro and in nude mice in vivo to examine the effects of immediate testosterone boost on CRPC cells. In addition, a testosterone tolerant cell model was established by incremental acclimatization of VCaP cells to 1nM testosterone. The effects of androgen withdrawal and testosterone boosts on gene expression were assessed by quantitative real-time polymerase chain reaction, ELISA, and Western blots. Tumor cell proliferation was evaluated with a BrdU test. RESULTSTestosterone boosts on CRPC VCaP cells eliminate tumor cells to a higher extent than androgen withdrawal in androgen tolerant cells. The pronounced decrease of tumor cell proliferation was accompanied by a marked downregulation of AR expression regarding full-length AR and splice variant AR V7. CONCLUSIONSAcquiring castration resistance of prostate cancer cells by AR overexpression and amplification obviously sensitizes such cells to testosterone concentrations as low as physiological values. This introduces novel therapeutic means to treat CRPC with non-toxic measures and may find clinical implementation in intermittent androgen deprivation regimens. Prostate 73: 1699-1709, 2013. (c) 2013 Wiley Periodicals, Inc."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1002/pros.22711"],["dc.identifier.isi","000324923400010"],["dc.identifier.pmid","23868789"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28396"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","Testosterone Boosts for Treatment of Castration Resistant Prostate Cancer: An Experimental Implementation of Intermittent Androgen Deprivation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2018Journal Article
    [["dc.bibliographiccitation.firstpage","673"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Robotic Surgery"],["dc.bibliographiccitation.lastpage","678"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Welzel, G."],["dc.contributor.author","Ritter, M."],["dc.contributor.author","Heinrich, E."],["dc.contributor.author","Bolenz, C."],["dc.contributor.author","Trojan, L."],["dc.date.accessioned","2020-12-10T14:14:04Z"],["dc.date.available","2020-12-10T14:14:04Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s11701-018-0800-y"],["dc.identifier.eissn","1863-2491"],["dc.identifier.issn","1863-2483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71310"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","The concentration of console surgeons: prospective evaluation of the loss of attention in robotic-assisted procedures"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI